Latest news
Heron Therapeutics Withdraws 2026 Guidance as CINVANTI Patent Risk and Strategic Review Cloud Outlook - Yahoo FinanceYahoo Finance · Mon, 10 Aug 2026 15:05:39 GMTHRTX: Q2 net revenue grew to $37.7M, but guidance was withdrawn amid CINVANTI patent uncertainty - TradingViewTradingView · Mon, 10 Aug 2026 13:58:30 GMTHRTX: Q2 net revenue grew to $37.7M, but guidance was withdrawn due to CINVANTI patent uncertainty - TradingViewTradingView · Mon, 10 Aug 2026 13:32:09 GMT